Patients with rheumatoid arthritis discontinued approximately one-third of biologic therapies at 1 year and one-half at 2 years, according to research presented at the annual congress of the European League Against Rheumatism in Madrid.
“Studies have shown that patients sustain maximum benefit from RA treatment in the first two years — yet our data highlight significant discontinuation rates during this time period,” researcher Vibeke Strand, MD, clinical professor at Stanford University School of Medicine, said in a press release.
More »